Jul 8, 2011 by Brian Orelli, PhDHalf a Breakup Is Better Than No Breakup at AllPfizer keeps two divisions and puts two on the chopping block.
Jul 7, 2011 by Brian Orelli, PhDJ&J's Been BusyLast week HIV with Gilead, this week hep C with Pharmasset.
Jul 7, 2011 by Brian Orelli, PhDThe Good, Bad, and Ugly of Exelixis' Drug DelayToo bad there's no way to know which one it is.
Jul 5, 2011 by Brian Orelli, PhDDrug Approved, But No Fireworks YetThe second FDA approval for Bayer and Johnson & Johnson's Xarelto is more important.
Jul 1, 2011 by Brian Orelli, PhDWhat Will Cell Therapeutics Do With Your Money?Unfortunately the answer is probably, "buying a drug."
Jun 30, 2011 by Brian Orelli, PhDDendreon Increases Potential Output, More to ComeLos Angeles plant is approved.
Jun 30, 2011 by Brian Orelli, PhDBiotech Winners of a Repatriation HolidayBiotechs and dividend players will come out ahead.
Jun 30, 2011 by Brian Orelli, PhDMedical-Device Makers' Killer: Health-Care InflationHigh prices have painted their targets.
Jun 29, 2011 by Brian Orelli, PhDSo Much Insulin, So Little Use for ItMannKind settles its supply agreement with Merck.
Jun 29, 2011 by Brian Orelli, PhDMonsanto Is Back From the DeadRoundup makes a triumphant return, but investors should focus on the seed business.
Jun 28, 2011 by Brian Orelli, PhDThe Wrong Way to Pay DividendsHas Amgen missed the point of dividends?
Jun 28, 2011 by Brian Orelli, PhDHIV Drug Partnership Gets a BoostGilead and Johnson & Johnson hook up on a pair of new combo treatments.
Jun 27, 2011 by Brian Orelli, PhDData Galore, but Where's the FDA Approval?Presentations at the American Diabetes Association won't help with approvals.
Jun 27, 2011 by Brian Orelli, PhDDouble Ouch! 2 Monster Drops in 2 Trading Days Long approval delays will do that.
